Relative Potency Estimates Research Articles

Point and Interval Estimation in the Combination of Bioassay Results with Unequal Variances

Symmetric parallel-line biological assays involve the estimation of (log) relative potencies. The class of p(≥ 2) combination of symmetric parallel line bioassays are considered in this study. A large sample test for the equality of the several potencies is developed. An estimator and a confidence interval are proposed for the common relative potency parameter. The asymptotic distribution of the proposed test-statistic under the null hypothesis as well as under a contagious hypothesis is derived.

Point and Interval Estimation in the Combination of Bioassay Results with Unequal Variances

Symmetric parallel-line biological assays involve the estimation of (log) relative potencies. The class of p(> 2) combination of symmetric parallel line bioassays are considered in this study. A large sample test for the equality of the several potencies is developed. An estimator and a confidence interval are proposed for the common relative potency parameter. The asymptotic distribution of the proposed test-statistic under the null hypothesis as well as under a contagious hypothesis is derived.

Derivation and application of relative potency estimates based on in vitro bioassay results

AbstractRelative potency (REP) estimates are widely used to characterize and compare the potency of a wide variety of samples analyzed using in vitro bioassays. Relative potency estimates are generally calculated as a simple ratio: the EC50 of a well‐characterized standard divided by the EC50 of a sample. Such estimates are valid only when the dose‐response curves for the sample and standard are parallel and exhibit the same maximum achievable response (efficacy). These conditions are often either violated or cannot be demonstrated. As a result, there is a need to calculate and present REPs in a manner that addresses the potential uncertainties caused by violation of the assumptions of parallelism and equal efficacy. Multiple point estimates, over the range of responses from EC20 to EC80, can be used to derive relative potency ranges (REP20–80 range). The width of a REP20–80 range is directly proportional to the degree of deviation from parallelism between sample and standard dose‐response curves. Thus, REP20–80 ranges both test the assumption of parallelism and characterize the amount of uncertainty in an REP estimate resulting from deviation from parallelism. Although uncertainties due to unequal efficacy cannot be easily characterized mathematically, a systematic method for evaluating sample efficacy has been developed into a framework to guide the derivation and application of REP estimates based on in vitro bioassay results. Use of the systematic framework and REP20–80 ranges was illustrated using three sample data sets. It is hoped that the framework and discussion presented will facilitate the use of bioassay‐derived REP estimates to characterize samples of both known and unknown composition without ignoring the assumptions underlying REP estimation.

Relative potencies of individual polychlorinated naphthalenes to induce dioxin-like responses in fish and mammalian in vitro bioassays.

A growing body of evidence suggests that polychlorinated naphthalenes (PCNs) may be fairly widespread environmental contaminants. This may be cause for concern because exposure to PCNs has been linked to dioxin-like biological responses in a wide variety of species. This study used three in vitro bioassays to characterize the dioxin-like potency of 18 individual PCN congeners and 1 PCN metabolite. The PLHC-1 fish hepatoma cell bioassay was relatively insensitive to PCNs. At the concentrations tested, only 1, 4 di-CN and 2,4-dichloro-1-napthol caused significant induction of ethoxyresorufin O-deethylase (EROD) activity in the PLHC-1 assay. In vitro EROD and luciferase assays using recombinant H4IIE rat hepatoma cells were more responsive to PCNs. Structure-activity relationships were observed both in terms of the degree of chlorination and the positions of chlorine substitutions. Hexa-chlorinated naphthalenes (CNs), exhibiting relative potencies (REPs) around 10(-3) (relative to TCDD), were the most potent congeners tested. Penta-CNs were also rather potent, yielding REPs between 10(-3) and 10(-7). Tetra-, tri-, di-, and mono-CNs were less active. REPs for the active congeners were similar to those for some PCBs. The relative potency estimates reported here contribute to an emerging body of information that will aid determination of the relative contribution of PCNs to the total dioxin-like activity associated with environmental samples.

DERIVATION AND APPLICATION OF RELATIVE POTENCY ESTIMATES BASED ON IN VITRO BIOASSAY RESULTS

Relative potency (REP) estimates are widely used to characterize and compare the potency of a wide variety of samples analyzed using in vitro bioassays. Relative potency estimates are generally calculated as a simple ratio: the EC50 of a well-characterized standard divided by the EC50 of a sample. Such estimates are valid only when the dose-response curves for the sample and standard are parallel and exhibit the same maximum achievable response (efficacy). These conditions are often either violated or cannot be demonstrated. As a result, there is a need to calculate and present REPs in a manner that addresses the potential uncertainties caused by violation of the assumptions of parallelism and equal efficacy. Multiple point estimates, over the range of responses from EC20 to EC80, can be used to derive relative potency ranges (REP20–80 range). The width of a REP20–80 range is directly proportional to the degree of deviation from parallelism between sample and standard dose-response curves. Thus, REP20–80 ranges both test the assumption of parallelism and characterize the amount of uncertainty in an REP estimate resulting from deviation from parallelism. Although uncertainties due to unequal efficacy cannot be easily characterized mathematically, a systematic method for evaluating sample efficacy has been developed into a framework to guide the derivation and application of REP estimates based on in vitro bioassay results. Use of the systematic framework and REP20–80 ranges was illustrated using three sample data sets. It is hoped that the framework and discussion presented will facilitate the use of bioassay-derived REP estimates to characterize samples of both known and unknown composition without ignoring the assumptions underlying REP estimation.

Toxicology of protein allergenicity: prediction and characterization.

The ability of exogenous proteins to cause respiratory and gastrointestinal allergy, and sometimes systemic anaphylactic reactions, is well known. What is not clear however, are the properties that confer on proteins the ability to induce allergic sensitization. With an expansion in the use of enzymes for industrial applications and consumer products, and a substantial and growing investment in the development of transgenic crop plants that express novel proteins introduced from other sources, the issue of protein allergenicity has assumed considerable toxicological significance. There is a need now for methods that will allow the accurate identification and characterization of potential protein allergens and for estimation of relative potency as a first step towards risk assessment. To address some of these issues, and to review progress that has been made in the toxicological investigation of respiratory and gastrointestinal allergy induced by proteins, a workshop, entitled the Toxicology of Protein Allergenicity: Prediction and Characterization, was convened at the 37th Annual Conference of the Society of Toxicology in Seattle, Washington (1998). The subject of protein allergenicity is considered here in the context of presentations made at that workshop.

Characterisation, calibration and comparison by international collaborative study of international standards for the calibration of therapeutic preparations of FSH.

Therapeutic preparations of FSH, used primarily for treatment of infertility, are calibrated by in vivo bioassay against international standards (IS) derived from different sources deemed appropriate to their use according to pharmacopoeial monographs. Menotrophins, which have been used for several decades to treat infertility, have been calibrated against the IS for urinary FSH and LH (ISU) but are now being replaced by highly purified urinary FSH or rDNA-derived FSH (rFSH). The aim of this study was to evaluate two preparations of human rFSH and one preparation of highly purified urinary FSH as candidate WHO IS for bioassay in an international collaborative study by 27 laboratories in 12 countries, and to characterise them in a range of in vitro bioassays and immunoassays. The biological activity of the three candidate standards was confirmed by all laboratories using all assays contributed to the study. Dose-response relationships by in vivo bioassay for any of the candidate standards did not differ significantly from that for the ISU. Dose-response relationships obtained in in vitro bioassays and immunoassays were also broadly similar among these preparations although dose-response lines for some preparations appeared to be non-parallel in some immunoassays. For each of the three candidate IS, estimates of the relative potency in terms of ISU by in vivo bioassay did not differ significantly between laboratories. In contrast estimates by immunoassays and in vitro bioassays showed significant differences between laboratories. Estimates of relative potency of the highly purified candidate IS materials in terms of one another exhibited less inter-laboratory variability than estimates in term of ISU. Each of the candidate standards showed adequate stability to serve as an IS. On the basis of the results of this study rFSH (code 92/642) was established as the first IS for FSH, human, recombinant for bioassay with an assigned unitage of 138 IU per ampoule and urinary FSH (code 92/512) was established as the first IS for FSH, human, urinary (urofollitropin) for bioassay with an assigned unitage of 121 IU per ampoule, based on their respective calibration by in vivo bioassay in terms of ISU. These assignments of unitage maintain continuity of unitage for preparations in therapeutic use and also appear to be consistent with one another.

Interpretation and estimation of relative potency in vaccines

The implication of relative potency varies between categories of assays. This review clarifies the meaning of the relative potency concept in each of several classes of assays commonly used to evaluate vaccines, so that an appropriate analytical procedure may be selected. Methods of estimating relative potency are reviewed and illustrated.

Comparison of non parallel immunoassay curves resulting from mixtures of competing antigens.

Relative potency is a measure that has been used for many years to summarize the comparison of dose-response curves in parallel line bioassays. When response curves for two preparations are not parallel the traditional definition of relative potency no longer applies. We review the concept of relative potency and show that, in some situations, it can be given meaning for non-parallel curves as the ratio of biological activity in full strength assay preparations. Under an assumption that non-parallel curves result from the competition of mixtures of antigens for receptor binding sites, estimation of relative potency for non-parallel curves can be accomplished. We show that estimation of models for both parallel curve and response attenuation situations may be accomplished within the framework of generalized linear models. This estimation depends on the ability to deal with non-linear parameters appearing in the link function, and an iterative algorithm depending on direct parameter updates is outlined. The topics discussed are illustrated with the analysis of data from two immunoassays conducted with veterinary vaccines. The models developed here depend in an essential way on the assumption of response attenuation by competing antigens. Our methods may not be appropriate for non-parallel curves caused by other phenomena.

Evaluation of Assay Designs for Assays Using Microtitre Plates: Results of a Study of In VitroBioassays and Immunoassays for Tumour Necrosis Factor (TNF)

Biological assays for tumour necrosis factor (TNF) are primarily based on its cytotoxic effect in tumour cell lines, and many of these bioassays are carried out using microtitre plates. Many immunoassays for TNF also routinely use microtitre plates. Data from an international collaborative study, carried out by twenty participants in nine countries, each of whom evaluated seven different ampouled preparations of human tumour necrosis factor alpha (hTNF-α), one ampouled preparation of human tumour necrosis beta (hTNF-β) and one ampouled preparation of mouse tumour necrosis factor alpha (mTNF-α) provided a unique opportunity for a broadly based evaluation and comparison of assay designs and results. The results of this evaluation can be applied to a wide range of in vitroassays based on cell cytotoxicity or proliferation. The results of this evaluation indicated that although it is difficult to achieve control of all factors which contribute to the variability of assay responses, assays may be designed to provide measures of the variation due to some factors and to improve reliability of estimates of relative potency.

Improved Shrinkage Estimation of Relative Potency

AbstractThis article considers the asymptotic estimation theory for the log relative potency in a symmetric parallel bioassay when uncertain prior information about the true log relative potency is assumed to be a known quantity. Three classes of point estimation, namely, the unrestricted estimator, the shrinkage restricted estimator and shrinkage preliminary test estimator are proposed. Their asymptotic mean squared errors are derived and compared. The relative dominance picture of the estimators is presented. Interestingly, proposed shrinkage preliminary test estimator dominates the unrestricted estimator in a range that is wider than that of the usual preliminary test estimator. Most importantly, the size of the preliminary test is much appropriate than the usual preliminary test estimator.

Relative Acute Neurotoxicity of Solvents: Isoeffective Air Concentrations of 48 Compounds Evaluated in Rats and Mice

Effect-air concentration regressions of 48 common solvents (aromatic, aliphatic, and chlorinated hydrocarbons, alcohols, ketones, acetates) were determined for 4-hr inhalation exposures in male rats and for 2-hr exposures in female mice. Inhibition of propagation and maintenance of the electrically evoked seizure discharge was used as a criterion of the acute neurotropic effect. The isoeffective concentrations in air were estimated by interpolation on the level of one-third of the maximum effect (ECC). ECC estimates ranged from 90 to 24,000 ppm and were several times lower than concentrations evoking behavioral inhibition and by one to two orders lower than concentrations inducing narcosis. Correlations between corresponding values in both species were high ( r > 0.9), indicating a relative independence of the estimates from experimental conditions. The relative potency estimates had only negligible correlation with octanol:water distribution coefficients or other physicochemical predictors for the whole sample of solvents, but moderate to high correlation ( r = 0.5 to 0.9) in homogenous groups of nonpolar solvents, permitting cautious predictions. When applied to known effective concentrations of some solvents on human performance and subjective state, the comparative potency procedure suggests that ceiling and STEL values of some solvents may not reliably protect workers from acute nervous depression.

Single-dose pharmacodynamics of diazepam and pentobarbital in substance abusers

The likelihood that a given drug will be misused is related to its ability to alter mood, feeling, thinking, and perception in a manner that is liked by substance abusers. The subjective and behavioral effects of diazepam (10, 20, and 40 mg), pentobarbital (120 and 240 mg as a positive control), and placebo (negative control), were evaluated in 12 subjects with histories of substance abuse by use of a double-blind, Latin square crossover study design. Drug administration was separated by a minimum of 3 days. Pharmacodynamic measures included subjective (euphoria, subject liking, sedation, and symptoms) and behavioral (signs and observed liking) responses. The time course and profile of subjective and behavioral responses were similar for diazepam and pentobarbital. Valid relative potency estimates for the pharmacodynamic measures indicated that diazepam is approximately 10 times as potent as pentobarbital. The study indicates that the reinforcing effects of diazepam are similar to pentobarbital in substance abusers.

Effects of β‐adrenoceptor agonists in human bronchial smooth muscle

1. We have investigated the potency and duration of action of isoprenaline and a range of beta-adrenoceptor agonists as relaxants of inherent tone in human superfused, isolated bronchial smooth muscle, a tissue reported to contain a homogeneous population of beta 2-adrenoceptors. 2. All of the beta-adrenoceptor agonists caused concentration-related inhibition of inherent tone, with isoprenaline having an EC50 of 27 nM. The rank order of agonist potency was: formoterol > or = -salmeterol > or = clenbuterol > fenoterol = isoprenaline > terbutaline > or = salbutamol > quinprenaline. 3. Relaxant responses to salmeterol were fully reversed by the selective beta 2-adrenoceptor blocking drug, ICI 118551, demonstrating the involvement of beta 2-adrenoceptors. 4. Rt50, i.e. the time taken for 50% recovery from the effects of an EC50 concentration of agonist, differed considerably between the different beta 2-adrenoceptor agonists. Most agonists were short-acting, having Rt50 values less than 13 min. Quinprenaline was of moderate duration, with an Rt50 value of > or = 20 min. In contrast, salmeterol was extremely long-acting, with no sign of recovery within 4 h. 5. Estimates of relative potency and duration of action were similar to those previously determined for these agonists in the guinea-pig isolated trachea. These results suggest, therefore, that guinea-pig trachea is a suitable alternative to human bronchus for the evaluation of the actions of beta-adrenoceptor agonists on airways smooth muscle.

Estimation of relative potency in multivariate parallel line bioassays

Finney (1978) has proposed using a composite response to estimate the relative potency of a test treatment with respect to a standard treatment, in the case of a multivariate parallel line bioassay. However, he assumes the coefficients in the composite response to be constants though they are estimated from the data itself. We provide two different methods of obtaining confidence intervals for this relative potency by using the exact variance. A method based on the use of delta technique is also proposed.

A GLM Approach to Quantal Response Models for Mixtures

Quantal response models for the combination of two different stimuli are considered as exponential family regression models. In the most general cases the models are nonlinear in the sense that there is no link to a linear predictor. Examples include probit models for correlated independent action and logit models for similar action. Parameters for spontaneous response are included. An extensive series of examples shows that these models can be easily fitted to real data using standard statistical software. Results include deviance statistics for goodness of fit, as well as maximum likelihood estimates of EC50s, relative potencies, and mixing parameters, together with their standard deviations. Likelihood ratio statistics for testing special models are easily computed, facilitating the analysis of complex data sets. Deviance residuals help detect lack of fit and individual outliers.

Relative potency estimates of acceptable residues and reentry intervals after nerve agent release

In the event of an unplanned release of a chemical warfare agent during any stage of the Chemical Stockpile Disposal Program, the potential exists for off-post contamination of drinking water, forage crops, grains, garden produce, and livestock. The more persistent agents, such as the organophosphate nerve agent VX, pose the greatest human health concern for reentry. A relative potency approach comparing the toxicity of VX to organophosphate insecticide analogues is developed and used to estimate allowable residues for VX in agricultural products and reentry intervals for public access to contaminated areas. Analysis of mammalian LD 50 data by all exposure routes indicates that VX is 10 3 to 10 4 times more toxic than most commercially available organophosphate insecticides. Thus, allowable residues of VX could be considered at concentration levels 10 3 to 10 4 lower than those established for certain insecticides by the U.S. EPA. Evaluation of reentry intervals developed for these organophosphate analogues indicate that, if environmental monitoring cannot reliably demonstrate acceptable levels of VX, restricted access to suspect or contaminated areas may be on the order of weeks to months following agent release. Planning for relocation, mass care centers, and quarantine should take this time period into account.

Estimation of Relative Potency with Sequential Dilution Errors in Radioimmunoassay

Sequential dilution is a very common procedure in radioimmunoassay, in which the dilution error will be accumulated from the highest to the lowest concentration. A simulated example in relative potency determination is used to demonstrate the potentially wrong conclusion that can be drawn, when the dilution error is not properly included in the model. A Bayesian method is used and an alternative approximation via maximum likelihood is proposed. An alternative experimental design is recommended to increase the precision of the inference.

Effect of caffeine on ibuprofen analgesia in postoperative oral surgery pain

Recent studies have demonstrated that caffeine acts as an analgesic adjuvant when combined with acetaminophen, aspirin, or their mixture. Our objective was to determine whether similar enhancement of analgesia could be demonstrated when caffeine is combined with ibuprofen. On a double-blind basis, a single oral dose of ibuprofen (50, 100, or 200 mg), a combination of ibuprofen, 100 mg, with caffeine, 100 mg, a combination of ibuprofen, 200 mg, with caffeine, 100 mg, or placebo was randomly assigned to 298 outpatients with postoperative pain after the surgical removal of impacted third molars. With a self-rating record, subjects rated their pain and its relief hourly for 8 hours. All active treatments were significantly superior to placebo, and the caffeine effect was significant for every measure of analgesia. Relative potency estimates indicated that the combination was 2.4 to 2.8 times as potent as ibuprofen alone. The combination also had a more rapid onset and longer duration of analgesic action. The analgesic adjuvancy of caffeine clearly extends to combinations with nonsteroidal anti-inflammatory drugs other than acetaminophen or aspirin.

Computational chemistry on a PC

AbstractWe describe a package of some IBM PC programs that may find application in computer‐aided molecular design. PCGEOM constructs and visualizes molecular models from bond lengths, bond angles, and dihedral angles, from Cartesian coordinates, or from stored fragments. It may prepare output files to be used as input for other programs, like CNDOB (conventional CNDO/2) or PCMEP using the bond increment (BI) method for the calculation of molecular electrostatic potentials. PCPROT is in preparation and will use Protein Data Bank coordinates to visualize and manipulate protein molecular models. Starting from these, it will calculate electrostatic potentials using the BI method and/or monopoles adjusted to reproduce ab initio values for amino acid residues. FSCF is based on a CNDO‐type approximation and uses strictly localized molecular orbitals in order to partition large molecules into a central fragment, a polarizable region, and a fully transferable environment. The partition allows one to handle relatively large systems with up to 200 atoms. To illustrate applications, we present estimation of relative inhibitory potencies of a series of substituted triazines on chicken liver dihydrofolate reductase.